SCHEMBL1793441

SCHEMBL1793441

C=CCC(O)(OC1CCCCC1)C(=O)O

nearest known ligand 0.31

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.31
CASP1 P29466 1/20 0.31
TSHR P16473 1/20 0.31
EPHX1 P07099 1/20 0.31
CCR2 P41597 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11033316 0.72 ALDH1A1 (0.39) ALDH1A1TSHR
SCHEMBL2129176 0.70 KEAP1 (0.36) ALDH1A1CASP1TSHRCCR2
SCHEMBL27826766 0.70 EPHX1 (0.35) EPHX1
SCHEMBL820423 0.69 EPHX1 (0.40) ALDH1A1EPHX1CCR2GAA
SCHEMBL28004359 0.68 EPHX1 (0.36) EPHX1CCR2
SCHEMBL5510657 0.68 EPHX1 (0.38) EPHX1
SCHEMBL28558883 0.67 CYP19A1 (0.43) ALDH1A1EPHX1CCR2
SCHEMBL6253845 0.66 L3MBTL1 (0.36) ALDH1A1TSHREPHX1
SCHEMBL1410774 0.66 GRM2 (0.41) ALDH1A1TSHRCCR2
SCHEMBL432459 0.66 CCR2 (0.37) ALDH1A1TSHREPHX1CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3684898-B1 METHOD FOR PRODUCING AN ACTIVE SUBSTANCE WAFER SYMRISE AG (DE) 2025-04-30 EP disclosed
US-20220411728-A1 HOME CARE PRODUCT OR FORMULATION SYMRISE AG (DE) 2022-12-29 US disclosed
US-11512267-B2 Active substance wafer SYMRISE AG (DE) 2022-11-29 US disclosed
EP-4061915-A1 HOME CARE PRODUCT OR FORMULATION Symrise AG (DE) 2022-09-28 EP disclosed
CN-114585715-A Home care products or formulations 西姆莱斯有限公司 2022-06-03 CN disclosed
WO-2021098950-A1 HOME CARE PRODUCT OR FORMULATION SYMRISE AG (DE) 2021-05-27 WO disclosed
EP-3740556-A1 TRANSPARENT ACTIVE SUBSTANCE RELEASE COMPOSITION AND METHOD FOR PRODUCING THE SAME Symrise AG (DE) 2020-11-25 EP disclosed
EP-3737427-A1 ARTICLE WITH SEPARATING LAYER FOR CONTROLLED RELEASE OF FRAGRANCES Symrise AG (DE) 2020-11-18 EP disclosed
EP-3737428-A1 ARTICLE PROVIDING SELECTIVE INTERCONNECTIVITY OF CARRIER MATERIALS COMPRISING FRAGRANCES Symrise AG (DE) 2020-11-18 EP disclosed
EP-3684898-A1 ACTIVE SUBSTANCE WAFER Symrise AG (DE) 2020-07-29 EP disclosed
US-20200216782-A1 ACTIVE SUBSTANCE WAFER SYMRISE AG (DE) 2020-07-09 US disclosed
WO-2019057294-A1 ACTIVE SUBSTANCE WAFER SYMRISE AG (DE) 2019-03-28 WO disclosed
EP-2336418-B1 Cavity containing odorous substances consisting of a polymer matrix SYMRISE AG (DE) 2013-08-28 EP disclosed
US-8513180-B2 Ethanol-free perfume oil microemulsion SYMRISE AG (DE) 2013-08-20 US disclosed
EP-2316408-B1 Ethanol-free perfume oil microemulsion SYMRISE AG (DE) 2013-07-03 EP disclosed
US-20120101020-A1 ETHANOL-FREE PERFUME OIL MICROEMULSION SYMRISE AG (DE) 2012-04-26 US disclosed
EP-2336418-A1 Cavity containing odorous substances consisting of a polymer matrix Symrise AG (DE) 2011-06-22 EP disclosed
EP-2316408-A1 Ethanol-free perfume oil microemulsion Symrise AG (DE) 2011-05-04 EP disclosed
EP-2031047-A1 Body and powder mixture for releasing CO2 Symrise GmbH & Co. KG (DE) 2009-03-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101020-A1 ETHANOL-FREE PERFUME OIL MICROEMULSION FFAR2, FFAR3, FFAR1 ALDH1A1 226/4885CASP1 2563/4885TSHR 4260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.